Navigation Links
OncoSec Medical to Present at the 25th Annual Roth Conference
Date:3/14/2013

SAN DIEGO, March 14, 2013 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that Punit Dhillon , President and CEO, will present at the 25th Annual Roth Conference at the Ritz-Carlton, Laguna Niguel in Dana Point, California, on Tuesday, March 19th at 8:00AM Pacific Time.

(Logo: http://photos.prnewswire.com/prnh/20120905/LA68078LOGO)

Mr. Dhillon will provide an overview of the Company and its milestones during the presentation, and will be conducting one-on-one meetings with investors who are registered to attend the conference. 

The presentation will be webcast live. To access the webcast, please visit  http://wsw.com/webcast/roth27/oncs/. The webcast will be archived for 90 days.

About the Annual Roth Conference

The 25th Annual Roth Conference is designed to provide investors with a unique opportunity to gain insight into emerging growth companies across a variety of sectors, including Business Services, Consumer, Cleantech, Industrials & Resources, Healthcare, Metals & Mining and Technology & Media.

The event is one of the largest of its kind in the U.S. It will feature presentations from hundreds of growth companies, expert panels and thousands of management one-on-one/small group meetings. To find out more, visit www.roth.com.

About OncoSec Medical Inc.

OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers. ImmunoPulse and NeoPulse th
'/>"/>

SOURCE OncoSec Medical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. OncoSec Medical Issues Letter to Shareholders
3. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
4. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
5. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
6. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
7. OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
8. OncoSec Granted New Patent from China
9. OncoSec to Present at Upcoming Healthcare and Investor Conferences
10. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
11. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... -- Pharmavite LLC announced that Timothy "Tim" Toll has ... Toll recently served as Pharmavite,s executive vice president of ... label and sales administration in the United ... will expand his responsibilities to include international sales, global ... to chief customer officer is part of a plan ...
(Date:7/23/2014)... 23, 2014 /PRNewswire-iReach/ -- The Centers for Medicare & ... Innovation Network-Quality Improvement Organization (QIN-QIO) contract to a partnership ... Effective August 1, WVMI will launch Quality Insights ... , Pennsylvania , Delaware ... Louisiana.  The Network will engage providers and the community ...
(Date:7/23/2014)... /PRNewswire-iReach/ -- Use of Risk Evaluation and Mitigation Strategies ... market entry results in $5.4 billion in lost savings ... by economic consulting firm Matrix Global Advisors ... Required by the Food and Drug Administration ... are intended to improve drug safety by ensuring that ...
Breaking Medicine Technology:Announcing a New Regional Approach to Medicare Quality Improvement 2New Analysis Finds $5.4 Billion In Annual Lost Savings From Strategies Geared Toward Delaying Generic Drug Entry 2
... Texas, July 14, 2011 Convergen LifeSciences ... 7,977,468 has been awarded by the U.S. Patent and ... Board of Regents and The Secretary, U.S. Department of ... of 23 patents, pending or issued worldwide, licensed exclusively to ...
... REDWOOD CITY, Calif., July 14, 2011 Codexis, Inc. (Nasdaq: ... in the 13th Annual Pacific Crest Global Technology Leadership Forum, ... Robert Lawson, Senior Vice President and Chief Financial Officer, will ... Biofuels and Renewable Chemicals," scheduled for August 8 at 12:30 ...
Cached Medicine Technology:Convergen LifeSciences Announces Patent Award 2
(Date:7/23/2014)... Karen Pallarito HealthDay ... In a wild day for Obamacare, two federal appeals courts ... financial subsidies provided to millions of Americans who bought health ... suggest that the matter is headed for a showdown before ... morning, the U.S. Appeals Court for the District of Columbia ...
(Date:7/23/2014)... at the emergency department, the drug ketamine can ... life-saving intubation, despite decades-old studies that suggested it ... systematic review of 10 recent studies of what ... are published online in Annals of Emergency ... Intracranial and Cerebral Perfusion Pressure and Health Outcomes: ...
(Date:7/23/2014)... 2014 AidJoy is delighted to announce that ... Zen on September 5, 2014 from 7:00 to 11:00 ... are expected to attend this semi-formal event. , "We are ... past six years," says Jess Dennis, Director of Operations and ... on this moment in AidJoy’s history before we launch into ...
(Date:7/23/2014)... Dallas, Texas (PRWEB) July 23, 2014 ... to 2020?, provides key market data on the ... provides value, in millions of US dollars, and ... US dollars), within market categories Cardiac Valve Repairs ... company shares and distribution shares data for each ...
(Date:7/23/2014)... 23, 2014) Statins, a class of drugs commonly ... risk of developing Barrett,s esophagus, according to a new ... the official journal of the American Gastroenterological Association. Obese ... statin use. , "Patients who received statins had a ... esophagus compared to non-users," said study author Hashem B. ...
Breaking Medicine News(10 mins):Health News:2 Courts, 2 Different Decisions on Key Obamacare Provision 2Health News:2 Courts, 2 Different Decisions on Key Obamacare Provision 3Health News:Ketamine can be a wonder drug for ER patients and their physicians 2Health News:AidJoy’s Inaugural Gala to be Held September 5, 2014 2Health News:Cardiovascular Prosthetic Devices Market in North America to 2020 Report Available at MarketOptimizer.org 2Health News:Cardiovascular Prosthetic Devices Market in North America to 2020 Report Available at MarketOptimizer.org 3Health News:Cardiovascular Prosthetic Devices Market in North America to 2020 Report Available at MarketOptimizer.org 4Health News:Cardiovascular Prosthetic Devices Market in North America to 2020 Report Available at MarketOptimizer.org 5Health News:Statin use decreases the risk of Barrett's esophagus 2
... for New York Blood Center (NYBC), NEW YORK, ... a blood drive on Monday, June 2 at 1011 ... School Gymnasium. Hours are from,9:30am-3:00pm, The Archdiocese of ... York,Blood Center; His Eminence Edward Cardinal Egan serves as ...
... WASHINGTON, May 30 The Department of,Veterans Affairs (VA) ... identified as being ill or injured from Operation,Enduring Freedom ... over 500,000 OEF-OIF veterans who have been,discharged from active ... "We promised to reach out to every OEF ...
... whole milk is just as effective, costs less and is ... is also commonly used as an oral contrast agent in conjunction ... , The study included 215 patients undergoing abdominal and pelvic CT, ... patients were given an IV contrast media; 115 were also given ...
... Results from a pivotal Phase III clinical ... once-daily, investigational anticoagulant medication, was superior in preventing ... knee replacement (TKR) surgery. The head-to-head study compared ... the current standard of care. , Data from ...
... May 30 Insulet Corporation,(Nasdaq: PODD ), ... its,OmniPod(R) Insulin Management System, today announced the company ... Obesity Conference.,Management is scheduled to present an overview ... June 6, 2008 at The Hotel Nikko in ...
... New Video ,Milestones in Oncology, Presentations at ... Society for Translational Oncology,(STO) is pleased to announce ... valuable video presentations for practicing,oncologists., (Logo: ... on the occasion of the 2008 Annual Meeting ...
Cached Medicine News:Health News:New York's Catholic Archdiocese Hosting June 2 Blood Drive 2Health News:VA Begins Next Phase of Combat Vet Outreach 2Health News:Rivaroxaban phase III pivotal data presented at EFORT annual meeting 2Health News:Rivaroxaban phase III pivotal data presented at EFORT annual meeting 3Health News:Society for Translational Oncology Launches Updated Website 2
... contact lens cleaning solution is ... and professionally proven cleaner. A ... resulting in a very effective ... cosmetic residue, salts, mucous and ...
Round knurled handle. Overall length 130 mm....
Alvis foreign body spud 4 3/4 inches, oval curette 1 x 3 mm with fine point....
Foreign body spud angled, lightly rounded tip....
Medicine Products: